Point72 Asia Singapore Pte. Ltd. Invests $84,000 in Mural Oncology plc (NASDAQ:MURA)

Point72 Asia Singapore Pte. Ltd. bought a new stake in Mural Oncology plc (NASDAQ:MURA) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,642 shares of the company’s stock, valued at approximately $84,000. Point72 Asia Singapore Pte. Ltd. owned about 0.16% of Mural Oncology at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BBR Partners LLC purchased a new position in shares of Mural Oncology during the second quarter worth about $31,000. Rhumbline Advisers acquired a new position in Mural Oncology during the second quarter worth approximately $34,000. Canada Pension Plan Investment Board purchased a new stake in Mural Oncology in the second quarter valued at approximately $70,000. Dimensional Fund Advisors LP purchased a new position in shares of Mural Oncology during the second quarter worth approximately $71,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Mural Oncology during the second quarter worth approximately $98,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Rodman & Renshaw started coverage on shares of Mural Oncology in a research note on Friday, June 28th. They set a “buy” rating and a $15.00 price target for the company.

Insider Transactions at Mural Oncology

In related news, CEO Caroline Loew sold 12,531 shares of the firm’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $2.91, for a total value of $36,465.21. Following the completion of the sale, the chief executive officer now owns 240,391 shares in the company, valued at $699,537.81. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Mural Oncology Stock Performance

Shares of MURA stock opened at $3.05 on Monday. The stock’s 50-day moving average price is $3.28 and its 200 day moving average price is $3.57. Mural Oncology plc has a 52-week low of $2.88 and a 52-week high of $17.00.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.90) by $0.04. As a group, equities research analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current year.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.